Erenumab-Aooe (Aimovig): Novel preventive treatment for migraine approved
Last Updated on June 29, 2018 by Joseph Gut – thasso
Migraine is a primary headache disorder characterized by recurrent headaches that are moderate to severe. Typically, the headaches affect one half of the head, are pulsating in nature, and last from two to 72 hours. Associated symptoms may include nausea, vomiting, and sensitivity to light, sound, or smell. The pain is generally made worse by physical activity. Up to one-third of people have an aura: typically a short period of visual disturbance that signals that the headache will soon occur. Occasionally, an aura can occur with little or no headache following it. Migraines are believed to be due to a mixture of environmental and genetic factors. About two-thirds of cases run in families. Changing hormone levels may also play a role, as migraines affect slightly more boys than girls before puberty and two to three times more women than men.
People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, hormonal changes, bright or flashing lights, lack of food or sleep and diet. Migraine and affects more than 10 percent of people worldwide.
The effectiveness of Erenumab-Aooe (Aimovig) for the preventive treatment of migraine was evaluated in three clinical trials. The first study included 955 participants with a history of episodic migraine and compared Erenumab-Aooe (Aimovig) to placebo. Over the course of six months, Erenumab-Aooe (Aimovig)-treated patients experienced, on average, one to two fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared Erenumab-Aooe (Aimovig) to placebo. Over the course of three months, Erenumab-Aooe (Aimovig)-treated patients experienced, on average, one fewer migraine day per month than those on placebo. The third study evaluated 667 patients with a history of chronic migraine and compared Erenumab-Aooe (Aimovig) to placebo. In that study, over the course of three months, patients treated with Erenumab-Aooe (Aimovig) experienced, on average, 2 ½ fewer monthly migraine days than those receiving placebo.
The most common side effects that patients in the clinical trials reported were injection site reactions and constipation.